Thelansis

  Hereditary angioedema (HAE) is a genetic disease characterized by the occurrence of transitory and recurrent subcutaneous and submucosal edemas resulting in swelling and abdominal pain. Epidemiology- Hereditary angioedema is estimated to affect 1 in 50,000 people. Type I is the most common, accounting for 85 percent of cases. Type II occurs in 15 percent of cases, and type III is rare. The competitive landscape of Hereditary angioedema (HAE) includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary. KOLs insights of Hereditary angioedema (HAE) across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs. Hereditary angioedema (HAE) Market Forecast : Patient Based Forecast Mode...